调强放疗联合替吉奥胶囊与康艾注射液同步增敏应用于中晚期宫颈癌的临床疗效

目的：探讨应用调强放疗联合替吉奥胶囊与康艾注射液治疗中晚期宫颈癌的临床疗效以及毒副反应。方法：选取98例中晚期宫颈癌患者作为研究对象，按照随机数字表法将其随机分为2组，每组49例。对照组患者应用调强放疗（IMRT）以及顺铂同步化疗，观察组患者应用调强放疗联合替吉奥胶囊与康艾注射液同步增敏，2组患者疗程均为5周。观察2组患者治疗后的临床症状改善情况，记录2组患者的生活质量（Karnofsky评分）和毒副作用情况。结果：治疗过程中，观察组患者消化道损伤、白细胞下降、血红蛋白及血小板的发生率分别为26.5%，38.8%，22.4%，12.2%，明显低于对照组相应的发生率46.9%，63.3%，51.0%，40.8%（P均<0.05）；2组患者在泌尿系统损伤发生率方面比较，差异无统计学意义（P>0.05）。治疗后，两组患者的Karnofsky评分均明显降低，与治疗前比较，差异有统计学意义（P<0.05或P<0.01）；对照组患者Karnofsky评分的降低程度相对观察组更为明显，差异有统计学意义（P<0.05）。观察组患者的生存率、局部复发率以及远处转移率分别为89.8%，10.2%和8.2%，明显优于对照组的71.4%，34.7%和33.6%，差异有统计学意义（P<0.05）。结论：调强放疗联合替吉奥胶囊与康艾注射液同步增敏应用于中晚期宫颈癌的临床有效率高于调强放疗联合顺铂化疗，此外该疗法还可减轻患者放化疗期间的不良反应，一定程度上提高患者的生活质量，有一定的临床应用前景。

Clinical efficacy on external exposure of intensity-modulated radiation therapy (IMRT) and synchronous enhancement with tegafur,gimeracil and oteracil potassium capsules and Kang'ai injection against intermediate and advanced cervical cancer

OBJECTIVE To explore clinical efficacy and side effects of external exposure of intensity-modulated radiotherapy and synchronous enhancement with tegafur, gimeracil and oteracil potassium capsules and Kang'ai injection against intermediate and advanced cervical cancer. METHODS Ninety eight patients with intermediate or advanced cervical cancer treated in our hospital were selected as subjects, and were randomly divided into two groups by using random number table method.Each group included 49 patients.Patients in control group received intensity-modulated radiation therapy (IMRT) and concurrent chemotherapy with cisplatin, while patients in observation group received IMRT and synchronous enhancement with tegafur, gimeracil and oteracil potassium capsules and Kang'ai injection.Patients in both groups were treated for 5 weeks.Patients of both group were observing for alleviation clinical symptoms, quality of life (Karnofsky score) and toxic and side effects were recorded. RESULTS During treatment, incidences of alimentary injuries, decrease of white blood cell count, hemoglobin and thrombocytopenia were 26.5%, 38.8%, 22.4% and 12.2% in observation group, respectively, significantly lower than those in control group, i.e., 46.9%, 63.3%, 51.0% and 40.8% (P<0.05).No significant difference was observed in incidence of urinary system injury between two groups (P>0.05).After treatment, Karnofsky scores of two groups were significantly reduced compared to those before treatment (P<0.05 or P<0.01).Decrease of Karnofsky score of control group was more significant than that of observation group (P<0.05).Survival rate, local recurrence rate and remote metastases were 89.8%, 10.2% and 8.2%, respectively in observation group, significantly superior to those in control group, i.e., 71.4%, 34.7% and 33.6% (P<0.05). CONCLUSION Clinical efficacy of IMRT and synchronous enhancement with tegafur, gimeracil and oteracil potassium capsules and Kang'ai injection applied in intermediate and advanced cervical cancer was superior to IMRT and concurrent chemotherapy with cisplatin.In addition, the treatment can reduce adverse reactions during chemoradiotherapy, improve patient's quality of life to some extent, and have certain clinical application prospect.